The development of the first drug in 30 years that modifies the disease - and not just the symptoms - of the most common form of dementia has given hope to patients. The drug Lecanemab is now undergoing a regulatory approval process in Australia and other countries in the world, but its exorbitant cost means few will be able to access it.
Listen to SBS Japanese Audio on Tue, Thu and Fri from 1pm on SBS 3.
Replays from 10pm on Tue, Thu and Sat on SBS1.
Listen to past stories from our podcast.
Share
